IGC Valuation

IGC Pharma Inc

Add to Watchlist

Advanced Chart

0.307

+0.003(+0.990%)

Overview
Forecast
Valuation

IGC Relative Valuation

IGC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IGC is overvalued; if below, it's undervalued.

Historical Valuation

IGC Pharma Inc (IGC) is now in the Fair zone, suggesting that its current forward PS ratio of 16.48 is considered Fairly compared with the five-year average of 8.33. The fair price of IGC Pharma Inc (IGC) is between 0.30 to 0.48 according to relative valuation methord.

Relative Value

Fair Zone

0.30-0.48

Current Price：0.31

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

3.74

P/B

Median3y

2.28

Median5y

2.24

-19.90

FCF Yield

Median3y

-28.29

Median5y

-26.33

Competitors Valuation Multiple

The average P/S ratio for IGC's competitors is 5.01, providing a benchmark for relative valuation. IGC Pharma Inc Corp (IGC) exhibits a P/S ratio of 16.48, which is 228.67% above the industry average. Given its robust revenue growth of 25.98%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap